CO5251399A1 - Derivados de purina - Google Patents
Derivados de purinaInfo
- Publication number
- CO5251399A1 CO5251399A1 CO00077985A CO00077985A CO5251399A1 CO 5251399 A1 CO5251399 A1 CO 5251399A1 CO 00077985 A CO00077985 A CO 00077985A CO 00077985 A CO00077985 A CO 00077985A CO 5251399 A1 CO5251399 A1 CO 5251399A1
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- phenyl
- cycloalkyl
- optionally substituted
- fluoroalkyl
- Prior art date
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 18
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 13
- -1 R3R3N-alkyl (C1-C6) Chemical group 0.000 abstract 9
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 7
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 6
- 125000001624 naphthyl group Chemical group 0.000 abstract 6
- 125000005843 halogen group Chemical group 0.000 abstract 5
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 5
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 abstract 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 4
- 125000001589 carboacyl group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 125000004428 fluoroalkoxy group Chemical group 0.000 abstract 2
- 125000003709 fluoroalkyl group Chemical group 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000002393 azetidinyl group Chemical group 0.000 abstract 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 abstract 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 abstract 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000002541 furyl group Chemical group 0.000 abstract 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 abstract 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 abstract 1
- 125000002757 morpholinyl group Chemical group 0.000 abstract 1
- 125000001715 oxadiazolyl group Chemical group 0.000 abstract 1
- 125000002971 oxazolyl group Chemical group 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000004193 piperazinyl group Chemical group 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 125000003373 pyrazinyl group Chemical group 0.000 abstract 1
- 125000002098 pyridazinyl group Chemical group 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 1
- 125000000168 pyrrolyl group Chemical group 0.000 abstract 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 abstract 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 abstract 1
- 125000001113 thiadiazolyl group Chemical group 0.000 abstract 1
- 125000000335 thiazolyl group Chemical group 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
- 125000001425 triazolyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
Abstract
Un compuesto de fórmula<EMI FILE="00077985_1" ID="1" IMF=JPEG >o una sal o solvato farmacéuticamente aceptable del mismo, en la que R1 es hidrógeno o alquilo C1 a C6 opcionalmente sustituido por 1 ó 2 sustituyentes seleccionados cada uno independientemente entre fenilo y naftilo, estando dicho fenilo y naftilo opcionalmente sustituido por alquilo C1-C6, alcoxi C1-C6, halo o ciano; A es un enlace o alquileno C1-C3, R2 es (i) hidrógeno, alquilo C1-C6, cicloalquilo C3-C7, fenilo o naftilo, estando dicho cicloalquilo C3-C7, fenilo o naftilo opcionalmente sustituido por alquilo C1-C6, fenilo, alcoxi (C1-C6)-alquilo(C1-C6), R3R3N-alquilo (C1-C6), fluoroalquilo (C1-C6), fluoroalcoxi (C1-C6), alcanoilo C2-C5, halo, -OR3, ciano, -COOR3, cicloalquilo C3-C7, -S(O)mR4, -NR3R3, -SO2NR3R3, -CONR3R3, -NR3COR4 o -NR3SO2R4, con la condición de que R2 no sea hidrógeno cuando A es un enlace, o (ii) cuando A es alquileno C2-C3, -R7R8, -OR3, -COOR3, -OCOR4, -SO2R4, -CN, -SO2R3R3, -NR3COR4 o -CONR3R3, o (iii) un heterociclo mono o bicíclico, de 4 a 11 miembros, unido a C, que tiene o bien desde 1 hasta 4 átomos de nitrógeno en el anillo, o bien 1 ó 2 átomos de nitrógeno y 1 átomo de oxígeno o 1 átomo de azufre en el anillo, opcionalmente sustituido el C por oxo, alcoxi (C1-C6)-alquilo (C1-C6), R3R3N-alquilo (C1-C6), fluoroalquilo C1- C6, fluoroalcoxi (C1-C6), fluoroalcanoilo C2-C5, halo, ciano, -OR5, R6, -COR5, -NR5R5, -COOR5, -S(O)mR6, -SO2NR5R5, -CONR5R5, -NR5SO2R6 o -NR5COR6 y opcionalmente sustituido el N por alcoxi (C1-C6)-alquilo (C1-C6), R3R3N-alquilo (C2-C6), fluoroalquilo C1-C6, fluoroalcanoilo C2-C5, R6, -COR5, -COOR5, -S(O)m R6, -SO2NR5R5 o -CONR5R5; - 2 - R3 es H, alquilo C1-C6, cicloalquilo C3-C7 o fenilo; R4 es alquilo C1-C6, cicloalquilo C3-C7 o fenilo; R5 es H, alquilo C1-C6, cicloalquilo C3-C7, fenilo, naftilo o het; R6 es alquilo C1-C6 , cicloalquilo C3-C7, fenilo, naftilo o het; cualquiera de los dos, R7 y R8, tomados junto con el átomo de nitrógeno al que están unidos, representan azetidinilo, pirrolidinilo, piperidinilo, morfolinilo, piperazinilo, homopiperidinilo, homopiperazinilo o tetrahidroisoquinolinilo, estando cada uno opcionalmente sustituido en un átomo de carbono del anillo por alquilo C1 -C6, cicloalquilo C3-C8, fenilo, alcoxi (C1-C6)-alquilo(C1-C6), R3R3N-alquilo (C1-C6), fluoroalquilo (C1-C6), -CONR3R3, -COOR3 o alcanoilo C2-C5, y opcionalmente sustituido en un átomo de carbono del anillo no adyacente a un átomo de nitrógeno del anillo por fluoroalcoxi-(C1-C6), halo, -OR3, ciano, -S(O)mR4, -NR3R3, -SO2NR3R3, NR3COR4 o -NR3SO2R4, y estando dichos piperazin-1-ilo y homopiperazin-1-ilo opcionalmente sustituidos en el átomo de nitrógeno del anillo no unido a A por alquilo C1-C6, fenilo, alcoxi (C1-C6)-alquilo (C2-C6), R3R3N-alquilo (C2-C6), fluoroalquilo C1-C6, alcanoilo C2-C5, -COOR4, cicloalquilo C3-C8, -SO2R4, -SO2NR3R3 o -CONR3R3, o R7 es H, alquilo C1-C6, cicloalquilo C3-C8, fenilo o bencilo y R8 es H, alquilo C1-C6, cicloalquilo C3-C8, fenilo, bencilo, fluoroalquilo C1-C6, -CONR3R3, -COOR4, alcanoilo C2-C5 o -SO2NR3R3; m es 0, 1 ó 2 ; y "het", usado en las definiciones de R5 y R6, significa pirrolilo, imidazolilo, triazolilo, tienilo, furilo, tiazolilo, oxazolilo, tiadiazolilo, oxadiazolilo, piridinilo, pirimidinilo, piridazinilo, pirazinilo, quinolinilo, isoquinolinilo, bencimidazolilo, quinazolinilo, ftalazinilo, benzoxazolilo o quinoxalinilo unido a C, cada uno opcionalmente sustituido por alquilo C1-C6 alcoxi C1-C6, ciano o halo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9924363.6A GB9924363D0 (en) | 1999-10-14 | 1999-10-14 | Purine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5251399A1 true CO5251399A1 (es) | 2003-02-28 |
Family
ID=10862760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO00077985A CO5251399A1 (es) | 1999-10-14 | 2000-10-12 | Derivados de purina |
Country Status (50)
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7427606B2 (en) * | 1999-02-01 | 2008-09-23 | University Of Virginia Patent Foundation | Method to reduce inflammatory response in transplanted tissue |
| US7378400B2 (en) * | 1999-02-01 | 2008-05-27 | University Of Virginia Patent Foundation | Method to reduce an inflammatory response from arthritis |
| GB0003960D0 (en) | 2000-02-18 | 2000-04-12 | Pfizer Ltd | Purine derivatives |
| US6921753B2 (en) | 2000-06-27 | 2005-07-26 | Pfizer Inc | Purine derivatives |
| GB0015727D0 (en) * | 2000-06-27 | 2000-08-16 | Pfizer Ltd | Purine derivatives |
| GB0022695D0 (en) | 2000-09-15 | 2000-11-01 | Pfizer Ltd | Purine Derivatives |
| WO2002096462A1 (en) * | 2001-05-25 | 2002-12-05 | Pfizer Inc. | An adenosine a2a receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases |
| CA2460911C (en) * | 2001-10-01 | 2011-08-30 | University Of Virginia Patent Foundation | 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof |
| ATE381336T1 (de) * | 2002-04-10 | 2008-01-15 | Univ Virginia | Verwendung von a2a adenosin rezeptor agonisten und anti-pathogene mittel enthaltenden kombinationen zur behandlung von entzündungskrankheiten |
| AR044519A1 (es) | 2003-05-02 | 2005-09-14 | Novartis Ag | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina |
| US20050033044A1 (en) * | 2003-05-19 | 2005-02-10 | Bristol-Myers Squibb Pharma Company | Methods for preparing 2-alkynyladenosine derivatives |
| GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
| GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
| US7605143B2 (en) * | 2004-08-02 | 2009-10-20 | University Of Virginia Patent Foundation | 2-propynyl adenosine analogs with modified 5′-ribose groups having A2A agonist activity |
| WO2006028618A1 (en) * | 2004-08-02 | 2006-03-16 | University Of Virginia Patent Foundation | 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity |
| US7442687B2 (en) * | 2004-08-02 | 2008-10-28 | The University Of Virginia Patent Foundation | 2-polycyclic propynyl adenosine analogs having A2A agonist activity |
| GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
| GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| EP1893593A1 (en) * | 2005-06-15 | 2008-03-05 | Pfizer Limited | 3-phenylazetidine derivatives as dopamine agonists |
| CN100352823C (zh) * | 2005-08-19 | 2007-12-05 | 浙江车头制药有限公司 | 一种腺嘌呤衍生物的制备方法 |
| KR20080049113A (ko) | 2005-10-21 | 2008-06-03 | 노파르티스 아게 | Ｉｌ-13에 대항한 인간 항체 및 치료적 용도 |
| GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
| WO2007092936A2 (en) * | 2006-02-08 | 2007-08-16 | University Of Virginia Patent Foundation | Method to treat gastric lesions |
| WO2007120972A2 (en) | 2006-02-10 | 2007-10-25 | University Of Virginia Patent Foundation | Method to treat sickle cell disease |
| US8188063B2 (en) * | 2006-06-19 | 2012-05-29 | University Of Virginia Patent Foundation | Use of adenosine A2A modulators to treat spinal cord injury |
| ATE502943T1 (de) | 2006-09-29 | 2011-04-15 | Novartis Ag | Pyrazolopyrimidine als pi3k-lipidkinasehemmer |
| RU2009120389A (ru) | 2006-10-30 | 2010-12-10 | Новартис АГ (CH) | Гетероциклические соединения в качестве противовоспалительных агентов |
| US8058259B2 (en) * | 2007-12-20 | 2011-11-15 | University Of Virginia Patent Foundation | Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists |
| WO2009087224A1 (en) | 2008-01-11 | 2009-07-16 | Novartis Ag | Pyrimidines as kinase inhibitors |
| SI2391366T1 (sl) | 2009-01-29 | 2013-01-31 | Novartis Ag | Substituirani benzimidazoli za zdravljenje astrocitomov |
| US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
| CA2770873A1 (en) | 2009-08-12 | 2011-02-17 | Novartis Ag | Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation |
| SG178454A1 (en) | 2009-08-17 | 2012-03-29 | Intellikine Inc | Heterocyclic compounds and uses thereof |
| IN2012DN01453A (es) | 2009-08-20 | 2015-06-05 | Novartis Ag | |
| WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
| US20130324526A1 (en) | 2011-02-10 | 2013-12-05 | Novartis Ag | [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase |
| JP5808826B2 (ja) | 2011-02-23 | 2015-11-10 | インテリカイン， エルエルシー | 複素環化合物およびその使用 |
| MA34969B1 (fr) | 2011-02-25 | 2014-03-01 | Irm Llc | Composes et compositions en tant qu inibiteurs de trk |
| CA2848809A1 (en) | 2011-09-15 | 2013-03-21 | Novartis Ag | 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines as c-met tyrosine kinase |
| CA2856803A1 (en) | 2011-11-23 | 2013-05-30 | Intellikine, Llc | Enhanced treatment regimens using mtor inhibitors |
| EP3964513A1 (en) | 2012-04-03 | 2022-03-09 | Novartis AG | Combination products with tyrosine kinase inhibitors and their use |
| WO2014151147A1 (en) | 2013-03-15 | 2014-09-25 | Intellikine, Llc | Combination of kinase inhibitors and uses thereof |
| TW201605450A (zh) | 2013-12-03 | 2016-02-16 | 諾華公司 | Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途 |
| WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
| AU2015294889B2 (en) | 2014-07-31 | 2018-03-15 | Novartis Ag | Combination therapy |
| TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5536419A (en) * | 1978-09-08 | 1980-03-14 | Yamasa Shoyu Co Ltd | 2-substituted adenosine derivative and its preparation |
| WO1988003147A1 (en) * | 1986-10-31 | 1988-05-05 | Warner-Lambert Company | Selected n6-substituted adenosines having selective a2 binding activity |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5877180A (en) * | 1994-07-11 | 1999-03-02 | University Of Virginia Patent Foundation | Method for treating inflammatory diseases with A2a adenosine receptor agonists |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| EP1121372B1 (en) * | 1998-10-16 | 2006-06-28 | Pfizer Limited | Adenine derivatives |
-
1999
- 1999-10-14 GB GBGB9924363.6A patent/GB9924363D0/en not_active Ceased
-
2000
- 2000-09-14 HN HN2000000204A patent/HN2000000204A/es unknown
- 2000-09-26 PA PA20008503501A patent/PA8503501A1/es unknown
- 2000-10-06 BR BR0011776-5A patent/BR0011776A/pt not_active IP Right Cessation
- 2000-10-06 AU AU75488/00A patent/AU768308B2/en not_active Ceased
- 2000-10-06 YU YU88901A patent/YU88901A/sh unknown
- 2000-10-06 AP APAP/P/2002/002478A patent/AP1442A/en active
- 2000-10-06 WO PCT/IB2000/001444 patent/WO2001027130A1/en active IP Right Grant
- 2000-10-06 KR KR1020027004748A patent/KR20020037774A/ko active IP Right Grant
- 2000-10-06 EA EA200101107A patent/EA004655B1/ru not_active IP Right Cessation
- 2000-10-06 HU HU0203483A patent/HUP0203483A2/hu unknown
- 2000-10-06 ES ES00964566T patent/ES2193990T3/es not_active Expired - Lifetime
- 2000-10-06 CA CA002387531A patent/CA2387531C/en not_active Expired - Fee Related
- 2000-10-06 CZ CZ20021223A patent/CZ20021223A3/cs unknown
- 2000-10-06 PL PL00354932A patent/PL354932A1/xx not_active Application Discontinuation
- 2000-10-06 DK DK00964566T patent/DK1220863T3/da active
- 2000-10-06 SI SI200030102T patent/SI1220863T1/xx unknown
- 2000-10-06 DZ DZ003159A patent/DZ3159A1/xx active
- 2000-10-06 EE EEP200200193A patent/EE200200193A/xx unknown
- 2000-10-06 JP JP2001530348A patent/JP3994007B2/ja not_active Expired - Fee Related
- 2000-10-06 EP EP00964566A patent/EP1220863B1/en not_active Expired - Lifetime
- 2000-10-06 NZ NZ515323A patent/NZ515323A/en unknown
- 2000-10-06 OA OA1200200102A patent/OA12059A/en unknown
- 2000-10-06 MX MXPA02003812A patent/MXPA02003812A/es active IP Right Grant
- 2000-10-06 IL IL14634200A patent/IL146342A0/xx unknown
- 2000-10-06 SK SK484-2002A patent/SK4842002A3/sk unknown
- 2000-10-06 AT AT00964566T patent/ATE238336T1/de not_active IP Right Cessation
- 2000-10-06 CN CNB008096287A patent/CN1151167C/zh not_active Expired - Fee Related
- 2000-10-06 GE GEAP20006243A patent/GEP20043269B/en unknown
- 2000-10-06 TR TR2002/00985T patent/TR200200985T2/xx unknown
- 2000-10-06 UA UA2002042943A patent/UA66945C2/uk unknown
- 2000-10-06 PT PT00964566T patent/PT1220863E/pt unknown
- 2000-10-06 DE DE60002356T patent/DE60002356T2/de not_active Expired - Fee Related
- 2000-10-12 CO CO00077985A patent/CO5251399A1/es not_active Application Discontinuation
- 2000-10-12 GT GT200000172A patent/GT200000172A/es unknown
- 2000-10-12 EC EC2000003712A patent/ECSP003712A/es unknown
- 2000-10-12 MY MYPI20004790A patent/MY136242A/en unknown
- 2000-10-13 AR ARP000105421A patent/AR023275A1/es unknown
- 2000-10-13 TN TNTNSN00202A patent/TNSN00202A1/fr unknown
- 2000-10-13 UY UY26397A patent/UY26397A1/es not_active Application Discontinuation
- 2000-10-13 PE PE2000001098A patent/PE20010755A1/es not_active Application Discontinuation
- 2000-10-13 SV SV2000000198A patent/SV2002000198A/es unknown
- 2000-10-16 US US09/688,624 patent/US6350735B1/en not_active Expired - Fee Related
-
2001
- 2001-11-16 IS IS6165A patent/IS6165A/is unknown
-
2002
- 2002-02-08 CR CR6584A patent/CR6584A/es not_active Application Discontinuation
- 2002-04-02 BG BG106569A patent/BG106569A/xx unknown
- 2002-04-09 MA MA26590A patent/MA26828A1/fr unknown
- 2002-04-10 NO NO20021692A patent/NO20021692L/no not_active Application Discontinuation
- 2002-04-11 ZA ZA200202849A patent/ZA200202849B/xx unknown
- 2002-11-29 HK HK02108605.8A patent/HK1047110B/zh not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5251399A1 (es) | Derivados de purina | |
| CO5261621A1 (es) | Derivados de purina | |
| CO5271668A1 (es) | Derivados de purina | |
| AR006906A1 (es) | Derivados de indazol sustituidos, composiciones farmaceuticas que los contienen, uso de los mismos e intermediarios de sintesis | |
| ES2190221T3 (es) | Derivados de indol y su uso para el tratamiento de enfermedades malignas y otras, que se basan en proliferaciones celulares patologicas. | |
| CO5130004A1 (es) | 1-aril-3-arilmetil-1,8-naftiridin-4(1h)-onas | |
| NZ512731A (en) | Tricyclic inhibitors of poly(ADP-ribose) polymerases | |
| AR044796A1 (es) | Derivados de pirido (2, 1-a) isoquinolina como inhibidores de la dpp iv | |
| AR048820A1 (es) | Tiadiazolidinonas como inhibidores de la glucogeno sintasa quinasa-3(gsk-3) | |
| BG101825A (en) | Pyrazol-4-yl-benzoyl derivatives and their use as herbicides | |
| GR3015616T3 (en) | Aryl-heteroaryl-carbinol derivatives having an analgesic activity. | |
| IL146319A0 (en) | Quinoline derivatives as inhibitors of mek enzymes | |
| JO2035B1 (en) | Pyrazine compounds | |
| ATE325113T1 (de) | Pharmacologisch wirksame pyrimidinderivate und verfahren zu deren herstellung | |
| PA8501801A1 (es) | Inhibidores triciclicos de polimerasas (adp - polirribosas) | |
| CO5320600A1 (es) | Agentes antibacterianos de 3-aminoquinazolin-2,4-dionas | |
| PE20020143A1 (es) | Carboxamidas heterociclicas como agentes antivirales | |
| AR053364A1 (es) | Compuesto de 1h-imidazo 84,5-c) piridin -2- ilo, composicion farmaceutica que lo comprende, proceso para prepararla y su uso para preparar un medicamento para tratamiento de cancer o artritis | |
| CO5231190A1 (es) | Combinaciones de compuestos activos del tipo de los cetoenoles ciclicos con piretroides | |
| CA2553704A1 (en) | Substituted benzimidazoles and their use for inducing apoptosis | |
| ES2182546T3 (es) | Imidazo(1,2a)azinas sustituidas como inhibidores selectivos de la cox-2. | |
| CA2382247A1 (en) | Azaindoles having serotonin receptor affinity | |
| PE17598A1 (es) | Quinolinas | |
| CO5150179A1 (es) | Derivados de n-etilpirimidin o (piridin)-2-(1,2-benzoisoxa- zol-3-il)-octahidro-2h-pirido[1,2-a]pirazina y sus composiciones farmaceuticas | |
| JO1216B1 (en) | Effective compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |